Blood Work to Get Before Starting Retatrutide (2026)
Before starting Retatrutide, get a comprehensive metabolic panel (CMP), HbA1c, fasting lipids, TSH, fasting insulin, complete blood count (CBC), and a urine microalbumin — at minimum. These baseline labs catch the conditions that make Retatrutide unsafe to start and establish the reference points your prescriber needs to measure your metabolic response over time.
The Short Answer
Retatrutide is a GLP-1/GIP/Glucagon triple agonist — the most potent peptide in its class as of 2026 — which means it drives more aggressive metabolic shifts than semaglutide or tirzepatide. That potency is exactly why baseline labs are non-negotiable, not optional paperwork. Your liver enzymes, kidney function, thyroid markers, and glucose metabolism will all change on Retatrutide, sometimes significantly in the first 8–12 weeks. Without baseline values, you cannot tell what the drug is doing versus what was already there.
The second reason is contraindication screening. Retatrutide carries a black box warning for thyroid C-cell tumors in rodent models — the same warning shared by other GLP-1 class drugs — meaning a baseline TSH and any history of medullary thyroid carcinoma or MEN2 must be evaluated before dose one. Pancreatic enzyme elevation (lipase, amylase) is another pre-screen target, since active pancreatitis is an absolute contraindication.
Expect your prescriber to order this panel 2–4 weeks before your start date so results are in hand before titration begins. Some compounding and telehealth providers will clear you with a subset of these labs — that is a red flag. A responsible Retatrutide protocol requires the full panel.
Key Factors to Consider
HbA1c and fasting glucose: Retatrutide produces significant glucose-lowering. If your HbA1c is above 8.0% or you are on insulin or sulfonylureas, your prescriber needs to adjust your diabetes medications proactively — hypoglycemia risk is real within the first 4–6 weeks of titration.
Liver function (AST, ALT, GGT): Elevated transaminases above 3x the upper limit of normal at baseline may warrant delaying the start. Retatrutide drives rapid fat mobilization, which can temporarily stress the liver — knowing your starting point is critical for monitoring.
Thyroid panel (TSH, free T4): GLP-1 receptor agonists are contraindicated in personal or family history of medullary thyroid carcinoma. TSH also establishes whether subclinical hypothyroidism is contributing to your weight — a condition Retatrutide will not fix on its own.
Lipase and amylase: Active pancreatitis disqualifies you from starting. Subclinical elevation (1.5–2x normal) should trigger imaging and shared decision-making before you proceed. Do not skip this panel because you feel fine — pancreatitis can be asymptomatic in early stages.
Kidney function (creatinine, eGFR, urine microalbumin): Rapid weight loss on Retatrutide can alter creatinine clearance and dehydration risk increases during nausea phases. An eGFR below 30 mL/min/1.73m² warrants nephrology consult before starting.
Fasting insulin and HOMA-IR: These are not always standard on routine panels but matter for Retatrutide candidates. Your degree of insulin resistance determines how aggressive your dose titration should be and gives your prescriber the clearest picture of your metabolic starting point.
Recommended Pre-Retatrutide Lab Panel
Lab Test | Why It Matters for Retatrutide | Threshold That Changes the Plan |
|---|---|---|
HbA1c | Baseline glucose control; hypoglycemia risk if on diabetes meds | >8.0% — adjust concurrent medications first |
Fasting glucose | Acute glucose status vs. long-term trend | >126 mg/dL — confirm T2D management plan |
CMP (full metabolic panel) | Liver enzymes, kidney function, electrolytes | AST/ALT >3x ULN — delay start |
CBC | Rules out anemia, infection, blood disorders | Significant anemia — evaluate before starting |
Fasting lipid panel | Baseline for tracking cardiovascular benefit | Triglycerides >500 mg/dL — treat before starting |
TSH + free T4 | Thyroid contraindication screen; hypothyroidism check | Any MTC/MEN2 history — absolute contraindication |
Lipase + amylase | Pancreatitis contraindication screen | >2x ULN — imaging and consult required |
Urine microalbumin | Early kidney damage marker; dehydration monitoring | Elevated — nephrology review before starting |
Fasting insulin / HOMA-IR | Insulin resistance severity; titration guidance | High HOMA-IR — confirms strong candidacy |
eGFR (from CMP) | Kidney filtration rate; safety during rapid weight loss | <30 mL/min/1.73m² — nephrology consult |
Who This Is Right For
If you have a BMI above 30 with no current diabetes medications, your pre-start panel is relatively straightforward — CMP, HbA1c, lipids, TSH, lipase, CBC, and microalbumin will cover you. Expect results in 3–5 business days and a start date within 2–4 weeks.
If you have Type 2 diabetes managed with metformin only, your prescriber needs your HbA1c and fasting glucose before titrating. Retatrutide may allow you to reduce metformin dose within 8–12 weeks — baseline labs make that conversation data-driven.
If you have a history of NAFLD or elevated liver enzymes, push for a GGT in addition to the standard CMP, and consider a FibroScan or liver ultrasound as a baseline imaging reference. Retatrutide can improve fatty liver — but you need before-and-after data to confirm it.
If you are post-bariatric surgery seeking additional weight loss, add a full micronutrient panel (B12, folate, iron, zinc, vitamin D) — GLP-1 class drugs reduce appetite further and can accelerate nutrient deficiency in this population.
Who Should Look Elsewhere
If your lipase or amylase comes back above 2x the upper limit of normal, Retatrutide is not the right starting point. Resolve the underlying pancreatic issue first. Starting a GLP-1/GIP/Glucagon triple agonist with active or subclinical pancreatitis is a serious safety risk.
If you or a first-degree relative has a history of medullary thyroid carcinoma or MEN2 syndrome, the entire GLP-1 drug class — including Retatrutide — is contraindicated. No lab result changes this. Explore non-GLP-1 obesity interventions.
If your eGFR is below 30 mL/min/1.73m², Retatrutide requires nephrology clearance before starting. The rapid fluid shifts and appetite suppression during titration carry added risk at severe renal impairment levels — this is not a population where you self-titrate and monitor at home.
Bottom Line
Get the full 10-test panel — not the abbreviated version. Retatrutide is the most potent weight loss peptide available in 2026, and that efficacy comes with metabolic changes your baseline labs need to capture. Any prescriber clearing you for Retatrutide without at minimum a CMP, HbA1c, TSH, lipase, and lipid panel is cutting corners that create liability for you, not them. If your labs come back clean, you are looking at a 2–4 week window before your first dose — use that time to establish your injection protocol and titration schedule.
